On Tuesday, InvenSense Inc (NYSE:INVN)’s shares declined -6.61% to $12.86.
InvenSense, Inc. (INVN) the leading provider of intelligent sensor system on chip (SoC) for Motion and Sound, recently declared results for its first quarter of fiscal year 2016, ended June 28, 2015.
Net revenue for the first quarter of fiscal 2016 was $106.3 million, up 7 percent from $99.3 million for the fourth quarter of fiscal 2015, and up 59 percent from $66.7 million for the first quarter of fiscal 2015.
Gross margin determined in accordance with U.S. generally accepted accounting principles (GAAP) was 42 percent for the first quarter of fiscal 2016, slightly down from 43 percent for the fourth quarter of fiscal 2015. GAAP gross margin for first quarter of fiscal 2016 comprised of stock-based compensation and related payroll taxes, and amortization of acquisition intangibles. Not taking into account these items, non-GAAP gross margin was 45 percent for the first quarter of fiscal 2016, slightly down from 46 percent for the fourth quarter of fiscal 2015.
InvenSense, Inc. designs, develops, markets, and sells micro-electro-mechanical system (MEMS) gyroscopes for motion tracking devices in consumer electronics. The company delivers intelligent sensor system on chip (SoC) for motion and sound in consumer electronic devices, such as smartphones, tablets, wearables, console and portable video gaming devices, digital television and set-top box remote controls, fitness accessories, sports equipment, digital still cameras, automobiles, ultra-books, laptops, hearing aids, stabilization systems, tools, navigation devices, remote controlled toys, and other household consumer and industrial devices.
Carnival Corp (NYSE:CCL)’s shares dropped -0.67% to $51.87.
Carnival Cruise Line and its partner Dr. Seuss Enterprises teamed up to celebrate the release of the new Dr. Seuss book, “What Pet Should I Get?” with celebrity book readings by Tampa Bay Rays all-star Evan Longoria aboard Carnival Paradise in Tampa and local broadcasting legend Angela Hill aboard Carnival Dream in New Orleans.
In conjunction with the event, Carnival is matching Longoria’s donation of $100 to Pet Pal Animal Shelter for every home run he hits during the 2015 season. The cruise line is also donating monies to the Tampa Bay and Louisiana chapters of the Society for the Prevention of Cruelty to Animals (SPCA).
Donning Dr. Seuss’ signature striped hat and surrounded by rescue dogs from the SPCA, Longoria and Hill delighted children with spirited readings of “What Pet Should I Get?” which is based on an original manuscript and accompanying sketches by Dr. Seuss, aka Ted Geisel, that was discovered in the La Jolla, Calif., home of the late beloved children’s author.
Following the reading, children and their chaperones joined The Cat in the Hat, Sam I am, and Thing 1 and Thing 2 for Carnival’s popular Green Eggs and Ham Breakfast with The Cat in the Hat and Friends, part of the line’s exclusive Seuss at Sea program.
Carnival Corporation operates as a cruise company worldwide. It provides vacations to various cruise destinations. The company offers cruise services under the Carnival Cruise Lines, Holland America Line, Princess Cruises, and Seabourn brand names in North America; and AIDA Cruises, Costa Cruises, Cunard, and P&O Cruises names in Europe, Australia, and Asia. It operates 100 cruise ships.
At the end of Tuesday’s trade, Bristol-Myers Squibb Co (NYSE:BMY)‘s shares dipped -0.75% to $64.85.
Bristol-Myers Squibb Company (BMY) declared a charitable donation to The Leukemia & Lymphoma Society (LLS). The donation will provide financial assistance for chronic myeloid leukemia (CML) patients who need assist paying for Polymerase Chain Reaction (PCR) testing, an important tool used in the diagnosis and monitoring of CML. The donation will also support LLS CML awareness activities focused on educating patients, caregivers and healthcare providers about the importance of continued monitoring with PCR testing.
he PCR test is used both in the diagnosis of CML and to monitor for cancerous cells after treatment has begun. It is the most sensitive testing method accessible, with the ability to detect a single cancerous cell among one million healthy cells. Recommendations suggest that a CML patient should receive a PCR test every three months for the first three years after diagnosis, and every three to six months thereafter based on how well their treatment is working. The average cost of a PCR test is $345 and can be as high as $500 per test. The program will assist insured and uninsured patients with out-of-pocket costs for PCR testing. The donation will also fund national CML awareness activities that will be undertaken by LLS’s 56 chapters, in addition to grassroots efforts through local netoperates of patients, volunteers and healthcare institutions.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, counting virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular.
Abengoa Yield PLC (NASDAQ:ABY), ended its Tuesday’s trading session with -5.96% loss, and closed at $23.21.
Abengoa Yield (ABY), the sustainable total return company that owns a diversified portfolio of contracted assets in the energy and environment sectors, stated revenues of $308.6 million for the six months ended June 30, 2015, representing an 82% enhance y-o-y and Further Adjusted EBITDA counting unmerged associates of $264.8 million, representing a 93% enhance contrast to the same period of 2014. Cash Accessible for Distribution for the six months reached $83.1 million, with a contribution in the second quarter of $44.6 million.
Solar assets have exceeded expectations due to better solar radiation levels than budget, especially in Europe. Wind assets in South America, representing a small portion of our portfolio, have practiced poorer than predictable wind resource. Mojave is delivering systematically above 90% of the performance model of a fully optimized plant, which is very successful for a large plant with only seven months of operations. Solana is also performing in line with its target, having reached record daily production above 4 GWh per day.
Abengoa Yield plc owns a portfolio of renewable energy, conventional power, and electric transmission line contracted assets in North America, South America, and Europe. The company’s renewable energy assets comprise 2 solar power plants each with a gross capacity of 280 megawatts (MW) in the United States; 1 on-shore wind farm with a gross capacity of 50 MW in Uruguay; and 2 solar power plants each with a gross capacity of 50 MW in Spain.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
